These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27555543)

  • 1. Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients.
    Rodriguez C; Suciu V; Poterie A; Lacroix L; Miran I; Boichard A; Delaloge S; Deneuve J; Azoulay S; Mathieu MC; Valent A; Michiels S; Arnedos M; Vielh P
    Mol Oncol; 2016 Nov; 10(9):1430-1436. PubMed ID: 27555543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China.
    Zhang Z; Yuan P; Guo H; Zhao L; Ying J; Wang M; Zhao H; Pan Q; Xu B
    Medicine (Baltimore); 2015 Jun; 94(24):e981. PubMed ID: 26091472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.
    Jacquemier J; Spyratos F; Esterni B; Mozziconacci MJ; Antoine M; Arnould L; Lizard S; Bertheau P; Lehmann-Che J; Fournier CB; Krieger S; Bibeau F; Lamy PJ; Chenard MP; Legrain M; Guinebretière JM; Loussouarn D; Macgrogan G; Hostein I; Mathieu MC; Lacroix L; Valent A; Robin YM; Revillion F; Triki ML; Seaume A; Salomon AV; de Cremoux P; Portefaix G; Xerri L; Vacher S; Bièche I; Penault-Llorca F
    BMC Cancer; 2013 Jul; 13():351. PubMed ID: 23875536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HER-2 overexpression and gene amplification of advanced breast cancers determined by fluorescence in situ hybridization in fine needle aspiration specimens].
    Zhang Z; Zhao L; Guo H; Guo L; Ling Y; Xu X; Zhao H; Pan Q
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):183-7. PubMed ID: 24785277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study.
    Acs B; Szekely N; Szasz AM; Lotz G; Szekely T; Istok R; Szekely E; Madaras L; Kulka J; Jaray B
    Diagn Cytopathol; 2016 Jun; 44(6):466-71. PubMed ID: 26990933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.
    Tsuda H; Kurosumi M; Umemura S; Yamamoto S; Kobayashi T; Osamura RY
    BMC Cancer; 2010 Oct; 10():534. PubMed ID: 20925963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions.
    Garuti A; Rocco I; Cirmena G; Chiaramondia M; Baccini P; Calabrese M; Palermo C; Friedman D; Zoppoli G; Ballestrero A
    Gynecol Oncol; 2014 Feb; 132(2):389-96. PubMed ID: 24269902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Badr NM; Zaakouk M; Zhang Q; Kearns D; Kong A; Shaaban AM
    Histopathology; 2024 Sep; 85(3):437-450. PubMed ID: 38651302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fine-Needle Aspiration Cytology versus Core-Needle Biopsy for Breast Lesions: A Dilemma of Superiority between the Two.
    Verma P; Sharma R; Sharma N; Gulati A; Parashar A; Kaundal A
    Acta Cytol; 2021; 65(5):411-416. PubMed ID: 34192704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
    Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
    J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer.
    Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Roka S; Bachleitner T; Kandioler D; Steger G; Mittlböck M; Jakesz R
    Wien Klin Wochenschr; 2004 Jan; 116(1-2):26-31. PubMed ID: 15030120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings.
    Gheni N; Westenberg D
    Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S123-S128. PubMed ID: 32108644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer.
    El Hadi H; Abdellaoui-Maane I; Kottwitz D; El Amrani M; Bouchoutrouch N; Qmichou Z; Karkouri M; ElAttar H; Errihani H; Fernandez PL; Bakri Y; Sefrioui H; Moumen A
    Gene; 2017 Mar; 605():114-122. PubMed ID: 28039034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
    Asogan AB; Hong GS; Arni Prabhakaran SK
    Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience.
    Slostad JA; Yun NK; Schad AE; Warrior S; Fogg LF; Rao R
    Cancer Med; 2022 Dec; 11(24):4954-4965. PubMed ID: 35733293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.
    Janeva S; Parris TZ; Nasic S; De Lara S; Larsson K; Audisio RA; Olofsson Bagge R; Kovács A
    BMC Cancer; 2021 Apr; 21(1):439. PubMed ID: 33879115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.